Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing
MWN-AI** Summary
Telo Genomics Corp. (TSXV: TELO; OTCQB: TDSGF) has successfully closed the second and final tranche of its non-brokered private placement offering of secured convertible debentures, raising gross proceeds of $545,000. This marks the culmination of an offering that totaled $1,385,000. The convertible debentures deliver a 15% annual interest, compounded quarterly, and are set to mature on December 15, 2026. Holders of these debentures have the option to convert them into common shares at a price of $0.05 each prior to the maturity date.
As part of the offering, Telo Genomics also issued 10,900,000 detachable warrants with an exercise price of $0.08, valid until March 6, 2027. The funds raised will primarily be allocated towards laboratory trials and general working capital. Additionally, Telo Genomics paid a cash finder's fee of $33,950 and issued 679,000 finder's warrants, also exercisable at $0.08 until March 6, 2028.
Notably, the offering includes related party transactions, where CFO John Price and director John Farlinger subscribed for a total of $45,000 in debentures. The company is relying on specific exemptions under Multilateral Instrument 61-101, as the total related party participation remains below 25% of the company's market capitalization.
Telo Genomics is at the forefront of developing diagnostic and prognostic tools through chromosomal telomere analysis, significantly advancing the field with its proprietary technology validated in over 160 peer-reviewed publications. The company's flagship product, Telo-MM, is aimed at enhancing treatment strategies for Multiple Myeloma patients, demonstrating a commitment to improving patient outcomes in oncology and other diseases. For further inquiries, interested parties can contact the company directly or visit their website at www.telodx.com.
MWN-AI** Analysis
Telo Genomics Corp.'s recent closing of its second tranche of secured convertible debentures raises important considerations for potential investors and existing shareholders. The cumulative $1.385 million raised highlights the company’s ongoing commitment to funding its innovative applications in liquid biopsy diagnostics, particularly in oncology and neurological diseases. With a robust interest rate of 15% compounded quarterly and the ability for investors to convert debentures into shares at $0.05, Telo Genomics has positioned itself as an enticing option for high-yield seekers in the biotech domain.
The issuance of 10.9 million warrants at an exercise price of $0.08 signifies strong potential for share price appreciation, especially considering the market's increasing reliance on minimally invasive diagnostics. Given the promising nature of Telo Genomics' technology and its strong track record, which includes over 160 peer-reviewed publications, investors might find the future upside compelling.
However, caution is advised. The investment hinges on regulatory approvals and the execution of Telo Genomics' strategic initiatives, so stakeholders should closely monitor developments that affect these aspects. The involvement of related parties in this transaction, including key executives, adds a layer of complexity—while it may imply confidence in the company’s outlook, investors should ensure that this doesn’t result in conflicts of interest or overly concentrated ownership.
The stock may experience volatility leading up to the warrants’ exercise period in 2027. Therefore, it could be wise to approach with a long-term perspective, while preparing for short-term fluctuations. Overall, potential investors should conduct thorough due diligence and weigh the risks against the promising landscape of diagnostic innovations that Telo Genomics is navigating.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement offering (the "Offering") of non-transferable secured convertible debentures ("Debentures") (see news releases dated January 19, 2026, February 18, 2026, and February 27, 2026) by issuing Debentures for gross proceeds of $545,000 (the "Second Tranche"), for aggregate gross proceeds from the Offering of $1,385,000.
The Debentures bear interest at a rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026 (the "Maturity Date"). The principal amount of the Debentures may, at the holder's election, at any time before the Maturity Date, be converted into common shares of the Company (each, a "Share") at a conversion price of $0.05 per Share. The Company has no right to prepay the Debentures prior to the Maturity Date.
In connection with the sale of the Debentures, the Company issued to the purchasers one transferable detachable warrant (a "Warrant") for every $0.05 of principal amount of the Debentures subscribed for. The Company issued an aggregate of 10,900,000 Warrants in connection with the Second Tranche. Each Warrant will be exercisable to acquire one Share at an exercise price of $0.08 per Share until March 6, 2027.
The proceeds raised from the Offering are expected to be used for lab trials and general working capital.
In connection with the Second Tranche, the Company paid cash finder's fees of $33,950 and issued 679,000 finder's warrants (each, a "Finder's Warrant"). Each Finder's Warrant will be exercisable to acquire one Share at an exercise price of $0.08 per Share until March 6, 2028.
The Debentures, Warrants and Finder's Warrants issued in connection with the Second Tranche and any securities issuable upon conversion or exercise will be subject to a four month and one day hold period, expiring July 7, 2026 in accordance with applicable Canadian securities laws.
The Offering is subject to certain conditions, including but not limited to receipt of all necessary approvals from the TSX Venture Exchange.
Pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"), the Company advises that two subscribers who purchased an aggregate of $45,000 of Debentures under the Second Tranche are considered to be related parties of the Company (the "Related Party Participation"). Specifically, John Price, the CFO of the Company, subscribed for $10,000 of Debentures and 200,000 Warrants, and John Farlinger, a director of the Company, subscribed for $35,000 of Debentures and 700,000 Warrants.
Each insider's participation in the Offering constitutes a "related party transaction" for the purposes of MI 61-101. The Company is relying on the exemptions from the formal valuation requirements contained in section 5.5(a) of MI 61-101 and from the minority shareholder approval requirements contained in section 5.7(1)(a) of MI 61-101, as the fair market value of the Related Party Participation does not exceed 25% of the Company's market capitalization, as determined in accordance with MI 61-101.
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
John Price
Chief Financial Officer
408-550-5767
info@telodx.com
555 Richmond Street West,
Toronto, ON, Canada, M5V 3B1
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", "intends", "expects", "anticipates" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements in this news release include statements regarding the Offering, the use of proceeds from the Offering, the conversion of Debentures, the exercise of Warrants and Finder's Warrants, and receipt of TSX Venture Exchange approval. These forward-looking statements are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including receipt of regulatory approvals and other risks. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286622
FAQ**
How is Telo Genomics Corp. leveraging its proprietary telomere technology to address the growing demand for liquid biopsies in Vancouver, such as Teledata Singapore Ltd TDSGF's advancements in oncology and neurological diagnostics?
What impact might Telo Genomics' recent funding from its private placement offering have on the biotech landscape in Vancouver, particularly in enhancing research and development facilities similar to those associated with Teledata Singapore Ltd TDSGF?
In what ways can the partnerships and investments in companies like Telo Genomics Corp. foster innovation in the life sciences sector in Vancouver, as evidenced by their work in liquid biopsies alongside players like Teledata Singapore Ltd TDSGF?
Given the regulatory environment in Vancouver, how does Telo Genomics plan to navigate the approval processes for its innovative diagnostic solutions, following their recent funding round that includes related parties like Teledata Singapore Ltd TDSGF?
**MWN-AI FAQ is based on asking OpenAI questions about Teledata Singapore Ltd (OTC: TDSGF).
NASDAQ: TDSGF
TDSGF Trading
0.0% G/L:
$0.034 Last:
6,461 Volume:
$0.034 Open:
